Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine add-on for opioid withdrawal symptoms
IRCT20090801002266N11Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid use disorder (OUD) comparing Memantine add-on with Placebo add-on (2 arms). Primary endpoints: Severity of opioid withdrawal symptoms and Reduction in withdrawal symptoms with add-on memantine. Started Nov 2019; status: completed.
02
Drugs
memantine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20090801002266N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N11.